Lucky Core Industries Limited (PSX: LCI) has successfully completed the acquisition of a manufacturing facility owned by Pfizer Pakistan Limited, located at B2 SITE Karachi. Along with the facility, LCI has also acquired certain pharmaceutical products, as announced to the main bourse on Monday.
The asset acquisition was finalized on September 6, 2024, in accordance with the Asset Purchase Agreements between the two parties, according to the stock filing.
The acquisition includes product registrations and trademarks for several pharmaceutical products from relevant Pfizer group entities. These products are Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin.
Following the announcement, LCI’s stock was trading at Rs. 1,019.99, marking an increase of 0.49 percent or Rs. 5, with a turnover of 22,708 shares on Monday.
